Weil, Wilson Advise On $213M Bard, SenoRx Merger
Aiming to expand its product offerings, C.R. Bard Inc. announced Wednesday that it would buy breast cancer medical device maker SenoRx Inc. in an all-stock deal worth roughly $213 million....To view the full article, register now.
Already a subscriber? Click here to view full article